<DOC>
	<DOCNO>NCT00104377</DOCNO>
	<brief_summary>Grass MATA ( modify pollen allergen tyrosine adsorbate ) develop provide pre-seasonal specific immunotherapy patient hypersensitivity grass rye pollen . Different dos Grass MATA administer immunological change follow treatment assess .</brief_summary>
	<brief_title>Induction Immunogenicity With Different Doses Grass MATA Subjects Allergic Grass Rye Pollen</brief_title>
	<detailed_description>Grass MATA MPL develop provide pre-seasonal specific immunotherapy patient prove type I hypersensitivity cross react grass pollen . The grass pollen extract modify glutaraldehyde produce active ingredient , allergoid . This modification reduce reactivity extract IgE antibody , thus reduce risk side effect . However , simultaneous reduction important immunological property , IgG T cell reactivity , see . MPL ( Monophosphoryl Lipid A ) , purify , detoxify glycolipid derive cell wall Salmonella minnesota , include product formulation adjuvant increase immunogenic effect product enhance switch allergen-specific TH2 TH1-like T cell profile . The purpose study ass specific immunological change ( IgG , IgG1 , IgG4 IgE ) allergic subject follow 2 subcutaneous injection different dos study medication ( Grass MATA placebo ) administer 3 week apart . The immunological change use assess performance R7 IgG reactivity assay range clinically efficacious dos .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Hypersensitivity , Immediate</mesh_term>
	<criteria>Females childbearing potential may enter study negative urine pregnancy test practice adequate contraception 3 month prior study continue study History least 1 season moderate severe seasonal rhinoconjunctivitis without bronchial asthma due IgE mediate allergy pollen grass rye Positive skin prick test grass pollen rye pollen allergen extract Positive skin prick test positive histamine control Negative skin prick test negative control Specific IgE grass rye document RAST equivalent test Moderate/severe allergy symptom past spring season Spirometry Screening demonstrate FEV1 &gt; = 80 % predict FEV1/FVC &gt; = 70 % . History presence acute subacute atopic dermatitis , chronic dermatitis , urticaria factitia , urticaria due physical/chemical influence skin condition might interfere interpretation skin prick test result Visual inspection forearm indicate potential problem conduct interpretation screen skin prick test ; forearm must available test History bronchial asthma , chronic obstructive pulmonary disease ( COPD ) , chronic condition lower respiratory tract History presence diabetes ( insulin dependent nondependent ) , cancer clinically significant cardiac , metabolic , renal , hepatic , gastrointestinal , dermatologic , venereal , hematologic , neurologic psychiatric disease disorder Any clinically significant abnormal laboratory value Visit 1 Clinically relevant sensitivity common perennial allergen : house dust mite , mold , epithelium ( cat , dog , horse ) . Subjects may enrol study test positive ( skin prick test RAST ) , current historical symptom perennial allergen . Clinically relevant sensitivity common springtime flowering plant : Birch , Oak , Sycamore , Beech , Ash Poplar . Subjects may enrol study test positive ( skin prick test RAST ) , current historical symptom springtime allergen . History autoimmune disease rheumatoid disease Subject allow receive adrenalin Subject disorder tyrosine metabolism ( i.e. , alcaptonuria , tyrosinemia ) Subject diseases interfere immune response receive medication , could influence result study Subject acute chronic infection History anaphylaxis , include anaphylactic food allergy , insect venom anaphylaxis , exercise drug induce anaphylaxis History angioedema History hypersensitivity excipients study medication History immunotherapy grass allergen extract Current therapy ÃŸblockers Currently receive antiallergy medication medication antihistaminic activity Subject positive drug abuse screen Visit 1 Subject participate clinical trial investigational medication within last 3 month Subject communicate reliably Investigator likely cooperate requirement study Subject pregnant lactating Use prohibit medication inadequate washout period prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Allergy</keyword>
	<keyword>Allergoid</keyword>
	<keyword>Specific Immunotherapy</keyword>
</DOC>